At the Exploring DNA Repair Pathways as Targets for Cancer Therapy conference, we presented findings on harnessing liquid biopsy to detect DDR biomarkers in CTCs.

We were proud to attend the 17th International Symposium on Translational Research in Oncology (ISTRO24).

We are delighted to announce our new partnership with the cutting-edge genomics and molecular diagnostics company, NuProbe USA, Inc.

We had a great time at ESMO24, engaging with scientists on the impact of liquid biopsy and circulating tumour cells on cancer research.

We are proud to have to have successfully launched our new HER2 assay at World CB & CDx24.

Dr. Marcel Nossmann from HiSS Diagnostics GmbH joins ANGLE HQ for two days of product training, enhancing our global team’s expertise and customer support.

We have two new exciting posters at the Biomarkers in Tissue and Blood poster session at EACR 2024 Congress 11:00 to 8:15PM.

Visit us at booth 77 to discuss how we can help enhance your cancer research with specialised circulating tumour cell (CTC) enrichment and analysis.

Anne-Sophie PAILHES-JIMENEZ, our Senior Director, Head of R&D, shared her insights on how CTCs, enriched using Parsortix® technology, can enhance liquid biopsy analysis.

New CellKeep™ poster revealed at New Frontiers in Liquid Biopsies: Data, Technology and Translational Potential on May 13th and 14th on board 034.